Novel Agents in Clinical Trials for AML
Source: A Focus on AML: Applying the Latest Research to Individualize Therapy

Video

Now Playing...
In this on-demand Webcast, Richard M. Stone, MD, provides expert perspective on optimal treatment of patients with acute myeloid leukemia.

Richard M. Stone, MD, has disclosed that he has received consulting fees from AbbVie, Agios, Amgen, Celator, Celgene, Janssen, Juno, Karyopharm, Merck, Novartis, Pfizer, Roche, Seattle Genetics, and Sunesis.

Downloads

  • Novel Agents in Clinical Trials for AML